Actavis’ nifedipine extended-release tablets are the generic equivalent of Bayer’s Adalat CC tablets and are available in 30mg and 60mg strengths. They can be used alone or in combination with other anti-hypertensive agents.
Doug Boothe, executive VP of US commercial & administration, said: “nifedipine XR is the first product launch from Actavis South Atlantic (formerly Abrika Pharmaceuticals) since the acquisition of Abrika in April 2007. It is going to be a valuable addition to our expanding product portfolio and solidifies our strategy to further grow our business in the controlled release segment along with other technically difficult markets.”
Annual sales of nifedipine XR tablets (Adalat CC and its generic equivalent) in the US were approximately $143 million for the twelve months ending March 2007, according to IMS health data.